Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 223-054-9 | CAS number: 3710-30-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Oral treatment with 1,7-Octadiene to rats for 90 consecutive days did not cause any effects of biological or toxicological significance at the low or intermediate doses of 100 or 300 mg/kg b.w./day.
The high dose of 1000 mg/kg b.w./day for 90 days caused an increased drinking water consumption of male animals, and increased plasma levels of total cholesterol and triglycerides in male and female animals. The kidney and liver weights were increased in male and female animals.
Additionally, the high dose group revealed histopathological changes in the kidney (chronic progressive nephropathy, tubule hypertrophy) and the stomach (non-glandular: hyperkeratosis, squamous cell hyperplasia), being slightly more severe in the male animals compared to the female animals. The histopathological changes observed in kidney and stomach are either generally reversible (hyperplasia and hyperkeratosis) after discontinuation of dosing or are a male rat-specific spontaneous age-related disease that may be exacerbated by chemicals, but a rodent disease of no relevance for extrapolation in human risk assessment.
No test item-related effects were noted in the testes and the epididymides of the male animals at any dose level.
In conclusion, the experimental no-observed-adverse-effect level (NOAEL) was at 300 mg 1,7 -Octadiene/kg b.w./day by oral administration
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 08-Oct-2015 to 07-Jan-2016
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 408 (Repeated Dose 90-Day Oral Toxicity Study in Rodents)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
- Species:
- rat
- Strain:
- Crj: CD(SD)
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS:
- Strain: Rat / CD® / Crl:CD(SD)
- Number and sex: 80 animals (40 males and 40 females)
- Breeder: Charles River Laboratories
- Body weigth: Males 251 - 287.8 g, Females 196.1 - 228.5 g
- Age: 61 days at 1st administration
ENVIRONMENTAL CONDITIONS:
- Diet: a certified commercial diet (ssniff® R/M-H V1534) ad libitum
- Water: tab water ad libitum
- Housing singly in MAKROLON cages (type III plus)
- Temperature: 22°C ± 3°C
- Rel. Humidity: 55% ± 15%
- Light/dark period: 12/12h - Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on oral exposure:
- The test item was administered orally at a constant volume per kilogram body weight (2 mL) once daily for 90 days.
- Analytical verification of doses or concentrations:
- yes
- Duration of treatment / exposure:
- 90 consecutive days
- Frequency of treatment:
- daily
- Dose / conc.:
- 100 mg/kg bw/day (nominal)
- Dose / conc.:
- 300 mg/kg bw/day (nominal)
- Dose / conc.:
- 1 000 mg/kg bw/day (nominal)
- No. of animals per sex per dose:
- 10
- Control animals:
- yes, concurrent vehicle
- Observations and examinations performed and frequency:
- CLINICAL SIGNS:
The animals were observed individually before and after dosing at each time of dosing for any signs of behavioural changes, reaction to treatment or illness, and additionally regularly throughout the working day. Cageside observations included skin/fur, eyes, mucous membranes, respiratory and circulatory systems, somatomotor activity and behaviour patterns.
NEUROLOGICAL SCREENING:
At the end of the treatment period, screening of sensory reactivity to stimuli of different types (e.g. auditory, visual and proprioceptive stimuli; based on Gad5), as well as the assessment of grip strength (Meyer6) and motor activity assessment was conducted for all animals.
In detail the test battery included testing of righting reflex, body temperature, salivation, startle response, respiration, mouth breathing, urination, convulsions, piloerection, diarrhoea, pupil size, pupil response, lacrimation, impaired gait, stereotypy, toe pinch, tail pinch, wire manoeuvre, hind leg splay, positional passivity, tremors, positive geotropism, limb rotation, auditory function.
MORTALITY:
Checks on mortality were made early in the morning and again in the afternoon of each day to look for dead or moribund animals.
BODY WEIGTH:
The weight of each rat was recorded at group allocation (test day -7), on test day 1 (before first administration), and once a week thereafter always on the same day of the week throughout the experimental period (test days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, 85 and 90).
FOOD CONSUMPTION:
The quantity of food left by individual animals was recorded on a weekly basis throughout the experimental period. The food intake per animal (g/animal/week) was calculated using the total amount of food given to and left by each rat in each group on completion of a treatment week.
DRINKING WATER CONSUMPTION:
The drinking water consumption was recorded weekly by weighing the water bottles when filled and the residues upon removal at the end of the test week. Any residue was discarded. Weekly mean values per animal were calculated.
LABORATORY EXAMINATIONS:
Blood samples were taken from the retrobulbar venous plexus under isoflurane anaesthesia from animals fasted overnight. The blood samples were collected at the end of test week 13 (on test day 91, before necropsy) and were used for haematological investigations, coagulation tests, clinical chemistry tests, and for bile acid determination.
Haematological parameters:
Haemoglobin content (HGB), erythrocytes (RBC), leucocytes (WBC), reticulocytes (Reti), platelets (PLT), haematocrit value (HCT), absolute and relative differential blood count, mean corpuscular volume (MCV), mean corpuscular haemoglobin (MCH), mean corpuscular haemoglobin concentration (MCHC).
Coagulation parameters:
Thromboplastin time (TPT), activated partial thromboplastin time (aPTT).
Clinical chemistry parameters:
Albumin, globulin, albumin/globulin ratio, bile acids, bilirubin (total), cholesterol, creatinine, glucose, protein, triglycerides, urea (in blood), calcium, chloride, potassium, sodium, alanine amino-transferase (ALAT), alkaline phosphatase (aP), aspartate aminotransferase (ASAT), lactate dehydrogenase (LDH)
Urinalysis:
Urine samples were collected from all animals fasted overnight on test day 91 (test week 13). Investigated parameters were volume, pH and specific gravity. The analytes of qualitative urinalyis were protein, glucose, bilirubin, urobilinogen, ketones, heamoglobin and nitrite. A microscopic examination of urine samples was carried out by centrifuging samples and spreading the resulting deposit on a microscope slide. The deposit was examined for the presence of epithelial cells, leucocytes, erythrocytes, organisms, further constituents (i.e. sperm, cassts), crystalluria.
OPHTHALMOLOGICAL AND AUDITORY EXAMINATIONS:
Examinations were performed pre-dose (test day 1, prior to first dosing) and in test week 13 (end of the treatment period, test day 90). The eyes were examined with a HEINE ophthalmoscope. Prior to examination, mydriasis was produced after instillation of STULLIN®10 eye drops into the conjunctival sacs.
The following ocular structures were examined:
• Adnexa oculi (i.e. lids, lacrimal apparatus), conjunctiva
• Cornea, anterior chamber
• Lens, vitreous body, fundus (retina, optic disc)
The auditory acuity was checked with a simple noise test. - Sacrifice and pathology:
- SACRIFICE:
Starting on test day 91 (approx. 24 hours after the last administration), the animals were dissected following a randomisation scheme. Animals not dissected on test day 91, were dosed again on test day 91 and dissected on test day 92. The animals were euthanized by carbon dioxide (CO2), exsanguinated by cutting the aorta abdominalis, weighed, dissected, and inspected macroscopically.The weights of the following organs of all animals were determined before fixation: adrenal gland, kidney, spleen, uterus (incl. cervix), brain, liver, testicle, prostate and seminal vesicles (with coagulating glands as a whole), epididymis, ovary, thymus, heart, pancreas. The paired organs (adrenal glands, gonads and kidneys) were identified as left or
right and weighed individually.
The organs or parts of organs of all animals were fixed in 7% buffered formalin. Eyes were preserved in Davidson's solution and testes in Bouin's solution for optimum fixation.
HISTOPATHOLOGY:
The organs listed below of all animals of groups 1 and 4 (control and high dose) were examined histologically after preparation of paraffin sections and haematoxylin-eosin (H & E) staining:
Adrenal gland (2)
Aorta abdominalis
Bone (os femoris with joint)
Bone marrow (os femoris)
Brain (cerebrum, cerebellum, brain stem)
Epididymis (2)
Eye with optic nerve (2)
Gross lesions observed
Heart (left and right ventricle, septum)
Intestine, small (duodenum, jejunum, ileum, incl. Peyer's patches, Swiss roll method)
Intestine, large (colon, rectum)
Kidney and ureter (2)
Liver
Lungs (with mainstem bronchi and bronchioles, preserved by inflation with fixative and then immersion)
Lymph node (1, cervical)
Lymph node (1, mesenteric)
Mammary gland
Muscle (skeletal, leg)
Nerve (sciatic)
Oesophagus
Ovary and oviducts (2)
Pancreas
Pituitary
Prostate and seminal vesicles with coagulating glands
Salivary glands (mandibular, parotid, sublingual)
Skin (left flank)
Spinal cord (3 sections)
Spleen
Stomach
Testicle (1)
Thymus
Thyroid (2) (incl. parathyroids)
Tissue masses or tumours (including regional lymph nodes)
Trachea (incl. larynx)
Urinary bladder
Uterus (incl. cervix)
Vagina
In addition, frozen sections of the heart, liver and one kidney were prepared, stained with Oil Red O, and examined microscopically, and the stomach and the kidneys (2) of the animals of group 2 (low dose) and group 3 (intermediate dose) were examined microscopically following H & E) staining.
Furthermore, a detailed histomorphological examination was performed on one testicle and one epididymis of all male animals of groups 1 to 4 (control and all dose groups) following H & E and PAS staining (with special emphasis on the qualitative stages of the spermatogenesis and the histopathology of the interstitial testicular structure). Sperm count an viabilty was assessed and sperm morphology was examined for all male animals. - Statistics:
- Data for toxicology and pathology were captured, as far as possible, using the departmental computerized systems (Provantis® Integrated preclinical software, version 9.4.0, Instem LSS Ltd., Stone, Staffordshire ST15 0SD, United Kingdom). Raw data not fully compatible with the computerized systems were maintained on paper according to appropriate SOPs. The test item-treated groups 2 to 4 were compared with the control group 1.
The following statistical methods were used for the data captured with the Provantis system: Multiple t-test based on DUNNETT, Exact Test of R.A. Fisher.
The following statistical methods were used for the data not captured with the Provantis system: STUDENT's t-test, chi²-test. - Clinical signs:
- effects observed, non-treatment-related
- Description (incidence and severity):
- A few statistically significant changes in comparison to the control animals were noted for forelimb and hindlimb grip strength in test week 13. However, all changes are considered to be coincidental effects; the slight change in comparison to the control group is within the normal range of biological variation and is considered to be without toxicological relevance and thus not to be related to the test item.
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- effects observed, non-treatment-related
- Description (incidence and severity):
- In all dose groups, the food consumption was statistically significantly (at p ≤ 0.05 or p ≤ 0.05) increased compared to the control group in various test weeks. However, all changes are considered coincidental as the slight differences to the control are in the normal range of biological variation.
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- effects observed, treatment-related
- Description (incidence and severity):
- The drinking water consumption of the male animals treated with 1000 mg/kg/day was constantly and always statistically significantly (at p ≤ 0.01) increased by up to 39% compared to the control group in test weeks 1 to 13. This effect is considered to be test item-related.
- Ophthalmological findings:
- no effects observed
- Haematological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Occassionally, statistically significant differences in haematological parameters compared to the control group were noted on test day 91 are not considered to be test item-related, because chagnes were only slight and within the normal range of biological variation, and/or changes were not dependent on dose. Changes consits of increase in basophilic granulocytes count (Baso) in males of the low-dose group, decrease in aPTT as well as increase on MCHC in males of the high-dose group.
- Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- The plasma levels of total cholesterol and of triglycerides were increased in the male and female animals treated with 1000 mg/kg/day compared to the control group. These changes are considered to be test item-related.
Occassionally, statistically significant differences in clinical biochemistry parameters compared to the control group were noted on test day 91 are not considered to be test item-related, because chagnes were only slight and within the normal range of biological variation, and/or changes were not dependent on dose. Changes consits of increase in ASAT in females of the low-dose group, and decrease in glucose, blood urea, chloride and sodium levels in males or females of the high-dose group. - Urinalysis findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- The relative urine volume of the male animals appeared to be increased by 82% at the mid-dose group and by 92% at the high-dose group compared to the control group on test day 91 (statistically significant at p ≤ 0.01). However, these apparent increases are due to the very low value of only 10.52 mL/kg
b.w./24 h observed for the control group and are considered not test item-related. Furthermore, the slight increase by 6% (statistically significant at p ≤ 0.05) noted for the pH value of the urine of the female high-dose animals compared to the control group is considered as coincidental and not test item-related. - Behaviour (functional findings):
- no effects observed
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- At the high dose of 1000 mg/kg b.w./day, statistically significantly (at p ≤ 0.01) increased relative and absolute kidney weights were noted for male and female animals, which can be correlated with the histopathological findings of chronic progressive nephropathy and tubule hypertrophy in the high-dose group. Further, the relative and absolute liver weights were slightly increased by up 26% at the high dose, the males (statistical significance at p ≤ 0.05 or p ≤ 0.01) being more affected than the females (no statistical significance).
The increased kidney and liver weights are considered to be test item-related.
Slightly increased relative and absolute kidney weights partly attaining statistical significance (at p ≤ 0.05 or p ≤ 0.01) that were noted in low- and mid-dose groups are not considered to be test item-related because of the following reasons:
- No corresponding histopathological findings in the kidney were noted for any animal of groups 2 and 3.
- At the low-dose group, the marginal alterations (without statistical significance) in comparison to the control group are within the normal range of biological variation. The statistically significant (at p ≤ 0.05) increase by 10.7% compared to the control noted for the relative weight of the right kidney of the female group 2 animals is considered to due to the slightly reduced average body weight of these animals in comparison to the control and not to be test item related.
- At the mid-dose group, the increases noted for the relative kidney weights (up to 18%, statistically significant at p ≤ 0.01) of the male animals compared to the control were much smaller than the respective absolute kidney weight changes. The changes are considered to be due to the higher average body weight of these animals in comparison to the control and not to be test item related. The differences in kidney weights (up to 16% compared to the control, mostly statistically significant at p ≤ 0.05) noted for the female animals of group 3 are considered to be due to 2 to 3 animals with relatively high kidney weights related to higher body weights compared to the control. Therefore, the effect in group 3 is also regarded as coincidental and not test item-related. - Gross pathological findings:
- no effects observed
- Neuropathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- For the high-dose animals, significant histopathological changes were observed for the kidney (chronic progressive nephropathy, tubule hypertrophy) and the stomach (non-glandular: hyperkeratosis, squamous cell hyperplasia), being slightly more severe in the male animals compared to the female animals. No corresponding findings were noted for the kidneys and the stomach of the animals of the low- and mid-dose groups. These kind of histopathological changes are either generally reversible (hyperplasia and hyperkeratosis) after discontinuation of dosing or are a male rat-specific spontaneous age-related disease that may be exacerbated by chemicals, but a rodent disease of no relevance for extrapolation in human risk assessment.
The coincidental findings in various organs in a small number of control and test item-treated animals are considered to be spontaneous organ changes and are thus not test item-related. - Histopathological findings: neoplastic:
- no effects observed
- Other effects:
- no effects observed
- Description (incidence and severity):
- No influence was noted on sperm count and sperm motility of male animals in all groups. The examination of the sperm morphology did not reveal any test item-related differences between the control group and the test item-treated groups in test week 13. These results are supported by the fact that the microscopic evaluation did not reveal any test item related effects on the male reproductive organs at the histomorphological level.
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 300 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- clinical biochemistry
- histopathology: non-neoplastic
- organ weights and organ / body weight ratios
- Key result
- Critical effects observed:
- yes
- Lowest effective dose / conc.:
- 1 000 mg/kg bw/day (nominal)
- System:
- urinary
- Organ:
- kidney
- Treatment related:
- yes
- Dose response relationship:
- yes
- Relevant for humans:
- no
- Key result
- Critical effects observed:
- yes
- Lowest effective dose / conc.:
- 1 000 mg/kg bw/day (nominal)
- System:
- gastrointestinal tract
- Organ:
- stomach
- Treatment related:
- yes
- Dose response relationship:
- yes
- Relevant for humans:
- no
- Conclusions:
- The test substance produces adverse effects on the kidney in rats (chronic progressive nephropathy, tubule hypertrophy) after consecutive treatment with 1,7-Octadiene at a dose level of 1000 mg/kg b.w./day for 90 days. The NOAEL is at 300 mg/kg b.w./day.
Reference
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEL
- 300 mg/kg bw/day
- Study duration:
- subchronic
- Species:
- rat
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Justification for classification or non-classification
The test substance is not classified for specific target organ toxicity, as the derived NOAEL from the 90-day subchronic study in rats is at 300 mg/kg b.w/day, and thus exceeding the trigger value of 100 mg/kg b.w./day for Category 2. The observed adverse effects on the non-glandular stomach epithelium (hyperplasia and hyperkeratosis) at a dose of 1000 mg/kg b.w./day are generally completely reversible after discontinuing of dosing. Moreover, chronic progressive nephropathy observed at 1000 mg/kg b.w./day is a spontaneous age-related disease that occurs in high incidence in the strains of rat commonly used in preclinical toxicology studies, exhibiting a male predisposition. It may be exacerbated by chemicals, but is considered to be a rodent disease of no relevance for extrapolation in human risk assessment.
Thus, the available data on specific target organ toxicity of 1,7 -Octadiene do not meet the criteria for classification according to Regulation (EC) 1272/2008, and are therefore conclusive but not sufficient for classification.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.